Aldosterone in renal disease.

Blockade of the renin-angiotensin-aldosterone system has proved effective in retarding the progression of renal disease in the remnant kidney model, as well as other experimental diseases, and most importantly, in a range of progressive human renal diseases. Attention has focused on the role of angiotensin II in propagating progression both by its hemodynamic and non-hemodynamic actions. Recent evidence, predominantly in the remnant kidney model, indicates that the drugs used to block this hormone system, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, also lower aldosterone levels. Aldosterone as well as angiotensin II thus appears to be instrumental in sustaining the hypertension and fibroproliferative destruction of the residual kidney.

[1]  R. Weiss,et al.  Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. , 2002, American journal of hypertension.

[2]  K. Tsuchiya,et al.  Aldosterone Breakthrough During Angiotensin II Receptor Antagonist Therapy in Stroke-Prone Spontaneously Hypertensive Rats , 2002, Hypertension.

[3]  N. Yamamoto,et al.  Aldosterone Is Produced From Ventricles in Patients With Essential Hypertension , 2002, Hypertension.

[4]  V. Buckalew,et al.  Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction , 2002 .

[5]  H. Mabuchi,et al.  Calcineurin Inhibition Attenuates Mineralocorticoid-Induced Cardiac Hypertrophy , 2002, Circulation.

[6]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[7]  G. Becker,et al.  Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. , 2001, The New England journal of medicine.

[8]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[9]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.

[10]  N. Chaturvedi Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.

[11]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[12]  H. Rennke,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy* , 2022 .

[13]  T. Meyer,et al.  Effect of Angiotensin II Blockade on Renal Injury in Mineralocorticoid-Salt Hypertension , 2000, Hypertension.

[14]  D. Vaughan,et al.  Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. , 2000, Kidney international.

[15]  C. Delcayre,et al.  Cardiac aldosterone production and ventricular remodeling. , 2000, Kidney international.

[16]  T. Hostetter,et al.  Role of dietary potassium in the hyperaldosteronism and hypertension of the remnant kidney model. , 2000, Journal of the American Society of Nephrology : JASN.

[17]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[18]  Giuseppe Remuzzi,et al.  Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria , 1999, The Lancet.

[19]  A. Delacourte Biochemical and Molecular Characterization of Neurofibrillary Degeneration in Frontotemporal Dementias , 1999, Dementia and Geriatric Cognitive Disorders.

[20]  F. Hutchison,et al.  Resistance to remnant nephropathy in the Wistar-Furth rat. , 1999, Journal of the American Society of Nephrology : JASN.

[21]  F. Luft,et al.  Intracellular actions of angiotensin II in vascular smooth muscle cells. , 1999, Journal of the American Society of Nephrology : JASN.

[22]  J. Cohn,et al.  Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. , 1998, European heart journal.

[23]  T. Hostetter,et al.  The renin-aldosterone axis in two models of reduced renal mass in the rat. , 1998, Journal of the American Society of Nephrology : JASN.

[24]  C. Stier,et al.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. , 1998, Hypertension.

[25]  T. Hostetter,et al.  Role of Renin-Angiotensin-Aldosterone System in the Progression of Renal Disease: A Critical Review , 1998 .

[26]  A. Struthers,et al.  Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. , 1997, Cardiovascular research.

[27]  I. Miyamori,et al.  Vascular aldosterone in genetically hypertensive rats. , 1997, Hypertension.

[28]  D. Vaughan,et al.  Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. , 1997, Kidney international.

[29]  T. Hostetter,et al.  Role of aldosterone in the remnant kidney model in the rat. , 1996, The Journal of clinical investigation.

[30]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[31]  A. Struthers Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. , 1996, Journal of cardiac failure.

[32]  J. Egido Vasoactive hormones and renal sclerosis. , 1996, Kidney international.

[33]  U. Ikeda,et al.  Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. , 1995, European journal of pharmacology.

[34]  I. Miyamori,et al.  Production of aldosterone in isolated rat blood vessels. , 1995, Hypertension.

[35]  I. Miyamori,et al.  3. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells , 1994, The Journal of biological chemistry.

[36]  M. Picken,et al.  Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. , 1994, Journal of the American Society of Nephrology : JASN.

[37]  R. Dilley,et al.  Mineralocorticoids, hypertension, and cardiac fibrosis. , 1994, The Journal of clinical investigation.

[38]  R. Spiro,et al.  Synthesis of Type VI Collagen by Cultured Glomerular Cells and Comparison of Its Regulation by Glucose and Other Factors With That of Type IV Collagen , 1994, Diabetes.

[39]  L. Kornel Colocalization of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells , 1994 .

[40]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[41]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[42]  W. G. Walker Hypertension-related renal injury: a major contributor to end-stage renal disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  K. Weber,et al.  Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. , 1992, The Journal of laboratory and clinical medicine.

[44]  T. Hostetter,et al.  Renin expression in renal ablation. , 1992, Hypertension.

[45]  T. Meyer,et al.  Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. , 1992, The Journal of clinical investigation.

[46]  L. Dworkin,et al.  Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. , 1992, Kidney international.

[47]  C. Alpers,et al.  Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. , 1992, Kidney international.

[48]  G. Hill,et al.  Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. , 1992, Kidney international.

[49]  A. Cowley,et al.  Long-term control of arterial blood pressure. , 1992, Physiological reviews.

[50]  T. Hostetter,et al.  Glomerular renin synthesis and storage in the remnant kidney in the rat. , 1991, Kidney international.

[51]  B. Delman,et al.  Adriamycin-induced increase in serum aldosterone levels: effects in riboflavin-sufficient and riboflavin-deficient rats. , 1990, Endocrinology.

[52]  J. Dominguez,et al.  Evidence that angiotensin-II and potassium collaborate to increase cytosolic calcium and stimulate the secretion of aldosterone. , 1989, Endocrinology.

[53]  L. Ruilope,et al.  Converting enzyme inhibition in chronic renal failure. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[54]  J. Miralles,et al.  Hyporeninemic hypoaldosteronism in diabetic patients with chronic renal failure. , 1988, American journal of nephrology.

[55]  D. Schlondorff The glomerular mesangial cell: an expanding role for a specialized pericyte , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  J. Bauer,et al.  Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. , 1986, Archives of internal medicine.

[57]  B. Brenner,et al.  Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. , 1986, The Journal of clinical investigation.

[58]  S. Linas,et al.  Effect of potassium depletion on two-kidney, one-clip renovascular hypertension in the rat. , 1985, Kidney international.

[59]  B. Brenner,et al.  Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. , 1984, The Journal of clinical investigation.

[60]  D. Young,et al.  Experimental Aldosterone Hypertension in the Dog , 1982, Hypertension.

[61]  R. Hené,et al.  Plasma aldosterone concentrations in chronic renal disease. , 1982, Kidney international.

[62]  J. Staessen,et al.  Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. , 1981, The Journal of endocrinology.

[63]  R. Tarazi,et al.  Sodium, Extracellular Fluid Volume, and Cardiac Output Changes in the Genesis of Mineralocorticoid Hypertension in the Intact Dog , 1979, Hypertension.

[64]  T. Berl,et al.  Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. , 1978, Kidney international.

[65]  P. Weidmann,et al.  Sodium, renin, aldosterone, catecholamines, and blood pressure in diabetes mellitus. , 1977, Kidney international.

[66]  S. Klahr,et al.  Pathogenesis of the glomerulopathy associated with renal infarction in rats. , 1976, Kidney international.

[67]  B. J. Tucker,et al.  Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. , 1976, The Journal of clinical investigation.

[68]  J. Baum,et al.  NATIONAL DRIED MILK , 1975, The Lancet.

[69]  T. Ferris,et al.  Renin secretion in renal hypertension. , 1970, Lancet.

[70]  Morrison Ab Experimentally induced chronic renal insufficiency in the rat. , 1962 .